0 citations0 references

Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients

Liver Transplantation2016Vol. 22(11), pp. 1536–1543

Citations Over TimeTop 10% of 2016 papers

Ryan M. Kwok, Joseph Ahn, Thomas D. Schiano, Helen S. Te, Darryn Potosky, Amber Tierney, Rohit Satoskar, Suzanne Robertazzi, Colleen Rodigas, Michelle Sang, Joshua J. Wiegel, Neal Patel, Janet Gripshover, Mohamed A. Hassan, Andrea D. Branch, Coleman I. Smith

Abstract

Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is associated with worse outcomes. The combination of ledipasvir (LDV) and sofosbuvir (SOF) has been approved for HCV treatment after LT, but there are limited data on the effectiveness and safety of LDV/SOF in the "real-world" setting. This multicenter study is the largest report to date on the effectiveness and safety of LDV/SOF in the post-LT setting. A total of 204 patients (72% male, 68% Caucasian, 66% genotype [GT] 1a, 21% METAVIR F3-F4, 49% treatment-experienced) were treated with LDV/SOF. The mean duration from LT to treatment initiation was 4.8 years. The overall sustained virological response rate 12 weeks after completion of therapy (SVR12) was 96%. Patients treated with 8 or 12 weeks of LDV/SOF without RBV experienced an SVR12 rate of 100% and 96%, respectively. Calcineurin inhibitors were used in 89% of patients, and 32% of patients underwent adjustment in immunosuppression during treatment. One episode of mild rejection, responsive to an increase in immunosuppression dosage, was observed. There was no graft loss attributed to HCV treatment. Four deaths occurred unrelated to HCV treatment, and no significant serious adverse events were documented. In conclusion, SOF and LDV with or without RBV for 8, 12, or 24 weeks in post-LT patients was effective and safe with a high SVR12 rate across a spectrum of GTs and stages of fibrosis. Liver Transplantation 22 1536-1543 2016 AASLD.

Citations Over TimeTop 10% of 2016 papers

Abstract

Related Papers